Please select the desired project time frame:
- July 2026
- January 2026
- July 2025
- January 2025
- July 2024
- January 2024
- July 2023
- January 2023
- July 2022
- January 2022
- July 2021
- January 2021
- July 2020
- January 2020
- July 2019
- January 2019
- July 2018
- January 2018
- July 2017
- January 2017
- July 2016
- January 2016
- July 2015
- January 2015
- July 2014
- January 2014
- July 2013
- January 2013
- July 2012
- January 2012
- July 2011
- January 2011
- July 2010
- January 2010
- July 2009
- January 2009
- July 2008
- January 2008
- July 2007
- January 2007
- July 2006
- January 2006
- July 2005
- January 2005
- July 2004
- January 2004
- July 2003
- January 2003
- July 2002
- January 2002
- July 2001
- January 2001
Start of funding 01.01.2024
Application of alchemical free energy methods for the development of new G protein-biased µ opioid receptor agonists
Prof. Dr. Peter Gmeiner
Friedrich-Alexander-University of Erlangen-Nuremberg
Department Chemie und Pharmazie
Prof. Dr. Michael K. Gilson
University of California, San Diego
Skaggs School of Pharmacy and Pharmaceutical Sciences
The G-protein-coupled µ-opioid receptor is responsible for both the analgesic effect of opioids such as morphine and fentanyl and their side effects, including addictive potential. While the analgesic effect is mediated via the G-protein signaling pathway, ß-arrestin transmits the side effects. The Gmeiner laboratory, which specializes in the development of novel GPCR ligands, succeeded in developing the G-protein-selective compound PZM21. The Gilson lab develops and uses computational chemistry methods to determine the binding affinity of new chemical compounds, also taking into account water displacement. As part of the collaboration, methods from the Gilson Lab will be used to further optimize PZM21 and investigate the signaling behavior of the µ-opioid receptor. The final goal will be the development of a new pain medication.